Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Fundamental Analysis

USA - NYSEARCA:OSTX - US68764Y2072 - Common Stock

1.77 USD
-0.13 (-6.84%)
Last: 10/30/2025, 8:04:03 PM
1.76 USD
-0.01 (-0.56%)
After Hours: 10/30/2025, 8:04:03 PM
Fundamental Rating

2

OSTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While OSTX seems to be doing ok healthwise, there are quite some concerns on its profitability. OSTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OSTX has reported negative net income.
In the past year OSTX has reported a negative cash flow from operations.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

OSTX has a Return On Assets of -157.62%. This is amonst the worse of the industry: OSTX underperforms 86.52% of its industry peers.
With a Return On Equity value of -240.68%, OSTX is not doing good in the industry: 69.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -157.62%
ROE -240.68%
ROIC N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for OSTX has been increased compared to 1 year ago.
OSTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M

2.2 Solvency

OSTX has an Altman-Z score of -0.48. This is a bad value and indicates that OSTX is not financially healthy and even has some risk of bankruptcy.
OSTX has a Altman-Z score (-0.48) which is comparable to the rest of the industry.
There is no outstanding debt for OSTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.48
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.03 indicates that OSTX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.03, OSTX is doing worse than 86.89% of the companies in the same industry.
A Quick Ratio of 1.03 indicates that OSTX should not have too much problems paying its short term obligations.
The Quick ratio of OSTX (1.03) is worse than 86.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

OSTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -128.56%.
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 26.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 437.78% on average over the next years. This is a very strong growth
EPS Next Y43.75%
EPS Next 2Y32.7%
EPS Next 3Y26.32%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y911.63%
Revenue Next 3Y437.78%
Revenue Next 5YN/A

3.3 Evolution

OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 5M 10M 15M 20M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OSTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as OSTX's earnings are expected to grow with 26.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.7%
EPS Next 3Y26.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OSTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OS THERAPIES INC

NYSEARCA:OSTX (10/30/2025, 8:04:03 PM)

After market: 1.76 -0.01 (-0.56%)

1.77

-0.13 (-6.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-18 2025-08-18/amc
Earnings (Next)11-14 2025-11-14
Inst Owners1.91%
Inst Owner Change1.99%
Ins Owners15.93%
Ins Owner Change0%
Market Cap59.35M
Revenue(TTM)N/A
Net Income(TTM)-16251900
Analysts82
Price Target13.26 (649.15%)
Short Float %1.86%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.05%
Min EPS beat(2)-194.12%
Max EPS beat(2)-61.98%
EPS beat(4)0
Avg EPS beat(4)-91.83%
Min EPS beat(4)-194.12%
Max EPS beat(4)-47.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-188.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.79
P/tB 8.79
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -157.62%
ROE -240.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z -0.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.57%
EPS Next Y43.75%
EPS Next 2Y32.7%
EPS Next 3Y26.32%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y911.63%
Revenue Next 3Y437.78%
Revenue Next 5YN/A
EBIT growth 1Y-56.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-142.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.18%
OCF growth 3YN/A
OCF growth 5YN/A

OS THERAPIES INC / OSTX FAQ

Can you provide the ChartMill fundamental rating for OS THERAPIES INC?

ChartMill assigns a fundamental rating of 2 / 10 to OSTX.


What is the valuation status for OSTX stock?

ChartMill assigns a valuation rating of 1 / 10 to OS THERAPIES INC (OSTX). This can be considered as Overvalued.


How profitable is OS THERAPIES INC (OSTX) stock?

OS THERAPIES INC (OSTX) has a profitability rating of 0 / 10.


What is the financial health of OS THERAPIES INC (OSTX) stock?

The financial health rating of OS THERAPIES INC (OSTX) is 5 / 10.